[Possibilities of influencing cardiovascular risk in type 2 diabetes mellitus by antidiabetic treatment Lowering of cardiovascular risk in treatment with liraglutide - Results of the LEADER].
The article summarizes current knowledge about the possibilities for influencing the cardiovascular risk in treatment of type 2 diabetes, especially focusing on the results of a prospective morbidity-mortality LEADER trial, which demonstrated the superiority of liraglutide in patients with very high cardiovascular risk. cardiovascular risk - LEADER - liraglutid - type 2 diabetes mellitus.